(Avdoralimab)Biosimilar Reference Antibody-GS40048 新品

货号：GS40048

Avdoralimab is a clinical-stage, fully human monoclonal antibody designed as a selective antagonist of the complement C5a receptor 1 (C5aR1, also known as CD88). It functions by specifically binding to C5aR1 on the surface of myeloid cells, thereby blocking the interaction with its potent pro-inflammatory ligand, C5a. This blockade aims to inhibit C5a-mediated recruitment and activation of neutrophils and other immune cells in inflammatory tissues. It is currently being evaluated in Phase II clinical trials, primarily investigated in combination with other agents for the treatment of severe COVID-19 pneumonia (to counteract the complement-driven "cytokine storm") and for certain cancers (to modulate the immunosuppressive tumor microenvironment).